Quick Answer
NEKTAR THERAPEUTICS reported Total Revenue of $55.23 million for fiscal year 2025.
NEKTAR THERAPEUTICS — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $55.23M -43.9% |
$98.43M +9.2% |
$90.12M -2.1% |
$92.06M -9.7% |
$101.91M -33.4% |
$152.91M +33.4% |
| Revenue (ASC 606) | $55.23M -43.9% |
$98.43M +9.2% |
$90.12M -2.1% |
$92.06M -9.7% |
$101.91M -33.4% |
$152.91M +33.4% |
| Net Income | -$164.08M -37.9% |
-$118.96M +56.9% |
-$276.06M +25.0% |
-$368.20M +29.7% |
-$523.84M -17.9% |
-$444.44M -0.9% |
| Diluted EPS | -$9.73 -12.1% |
-$8.68 -498.6% |
-$1.45 +26.4% |
-$1.97 +31.1% |
-$2.86 -14.9% |
-$2.49 +1.2% |
| Total Assets | $280.41M -7.7% |
$303.85M -23.7% |
$398.03M -44.0% |
$710.60M -36.4% |
$1.12B -27.4% |
$1.54B -22.2% |
| Cash and Equivalents | $15.12M -65.8% |
$44.25M +25.4% |
$35.28M -60.0% |
$88.23M +249.9% |
$25.22M -87.3% |
$198.96M +106.5% |
| Stockholders Equity | $89.83M +47.9% |
$60.74M -53.6% |
$130.99M -64.3% |
$366.64M -46.0% |
$679.51M -36.9% |
$1.08B -23.3% |
| R&D Expense | $117.33M -3.0% |
$120.91M +5.9% |
$114.16M -47.7% |
$218.32M -45.5% |
$400.27M -2.1% |
$408.68M -6.0% |
| Operating Income | -$140.10M -33.2% |
-$105.20M +60.1% |
-$263.68M +29.9% |
-$376.17M +15.7% |
-$446.10M -4.9% |
-$425.11M +3.4% |
| Shares Outstanding | 20.38M +64.5% |
12.39M -93.5% |
191.38M +1.5% |
188.56M +1.7% |
185.47M +3.0% |
180.09M +2.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.79M | -51.1% | +5.5% |
| Revenue (ASC 606) | September 30, 2025 | $11.79M | -51.1% | +5.5% |
| Net Income | September 30, 2025 | -$35.52M | +4.1% | +14.6% |
| Diluted EPS | September 30, 2025 | -$1.87 | +29.7% | +36.6% |
| Total Assets | September 30, 2025 | $301.35M | -2.1% | +45.2% |
| Cash and Equivalents | September 30, 2025 | $41.03M | +36.3% | -4.6% |
| Stockholders Equity | September 30, 2025 | $85.09M | +74.1% | +451.4% |
| R&D Expense | September 30, 2025 | $27.25M | -22.2% | -8.8% |
| Operating Income | September 30, 2025 | -$31.67M | +7.8% | +12.6% |
| Shares Outstanding | September 30, 2025 | 19.65M | -89.3% | +57.8% |
- NEKTAR THERAPEUTICS reported Total Revenue of $55.23 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -43.9% in Total Revenue compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Revenue (ASC 606) of $55.23 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -43.9% in Revenue (ASC 606) compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Net Income of -$164.08 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -37.9% in Net Income compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Diluted EPS of $9.73 per share (loss) for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -12.1% in Diluted EPS compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Total Assets of $280.41 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -7.7% in Total Assets compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Cash and Equivalents of $15.12 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -65.8% in Cash and Equivalents compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Stockholders Equity of $89.83 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed an increase of +47.9% in Stockholders Equity compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported R&D Expense of $117.33 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -3.0% in R&D Expense compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Operating Income of -$140.10 million for fiscal year 2025.
- NEKTAR THERAPEUTICS showed a decrease of -33.2% in Operating Income compared to the prior fiscal year.
- NEKTAR THERAPEUTICS reported Shares Outstanding of 20.38 million shares for fiscal year 2025.
- NEKTAR THERAPEUTICS showed an increase of +64.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: